BRAF and non-small cell lung carcinoma: Median OS and rwPFS with RW ICI plus PBC in the present study are similar to survival outcomes reported in clinical trials of pembrolizumab + chemotherapy in patients with aNSCLC (nonsquamous metastatic NSCLC: median OS = 22.0 mo, median PFS = 9.0 mo38), even though the proportion of patients with BRAF-mutated NSCLC in these clinical trials was likely low.